Cover Image
市場調查報告書

TauRx Therapeutics Ltd. 的產品平台分析

TauRx Therapeutics Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192844
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
TauRx Therapeutics Ltd. 的產品平台分析 TauRx Therapeutics Ltd. - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 31 Pages
簡介

TauRx Therapeutics Ltd. 是在新加坡設立總公司的製藥企業,以獨有的技術平台作為基礎,進行老年癡呆症及其他的神經退化性疾病治療藥的藥物研發、開發、商品化專門的業務。

本報告提供TauRx Therapeutics Ltd. 的治療藥開發平台的現狀及各開發階段比較分析、藥物標的、作用機制、給藥途徑、各分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

TauRx Therapeutics Ltd. 的基本資料

  • TauRx Therapeutics Ltd. 概要
  • 主要資訊
  • 企業資料

TauRx Therapeutics Ltd. :R&D概要

  • 主要的治療範圍

TauRx Therapeutics Ltd. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

TauRx Therapeutics Ltd. :開發中產品概況

  • 後期階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

TauRx Therapeutics Ltd. :藥物簡介

  • TRx-0237
  • G3-TAI
  • Small Molecule to Inhibit Alpha Synuclein for Parkinson's disease
  • G2 PD
  • Small Molecule for Alzheimer's Disease

TauRx Therapeutics Ltd. :開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

TauRx Therapeutics Ltd. :最新的開發平台資訊

TauRx Therapeutics Ltd. :開發暫停中的計劃

TauRx Therapeutics Ltd. :開發中止的開發中產品

  • 開發中止的開發中產品簡介

TauRx Therapeutics Ltd. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07717CDB

Summary

Global Markets Direct's, 'TauRx Therapeutics Ltd. - Product Pipeline Review - 2015', provides an overview of the TauRx Therapeutics Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TauRx Therapeutics Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of TauRx Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of TauRx Therapeutics Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the TauRx Therapeutics Ltd.'s pipeline products

Reasons to buy

  • Evaluate TauRx Therapeutics Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of TauRx Therapeutics Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the TauRx Therapeutics Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of TauRx Therapeutics Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of TauRx Therapeutics Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of TauRx Therapeutics Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • TauRx Therapeutics Ltd. Snapshot
    • TauRx Therapeutics Ltd. Overview
    • Key Information
    • Key Facts
  • TauRx Therapeutics Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • TauRx Therapeutics Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • TauRx Therapeutics Ltd. - Pipeline Products Glance
    • TauRx Therapeutics Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • TauRx Therapeutics Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • TauRx Therapeutics Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • TauRx Therapeutics Ltd. - Drug Profiles
    • TRx-0237
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G3-TAI
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Alpha Synuclein for Parkinson's disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G2 PD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • TauRx Therapeutics Ltd. - Pipeline Analysis
    • TauRx Therapeutics Ltd. - Pipeline Products by Target
    • TauRx Therapeutics Ltd. - Pipeline Products by Route of Administration
    • TauRx Therapeutics Ltd. - Pipeline Products by Molecule Type
    • TauRx Therapeutics Ltd. - Pipeline Products by Mechanism of Action
  • TauRx Therapeutics Ltd. - Recent Pipeline Updates
  • TauRx Therapeutics Ltd. - Dormant Projects
  • TauRx Therapeutics Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • TRx-0037
  • TauRx Therapeutics Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • TauRx Therapeutics Ltd., Key Information
  • TauRx Therapeutics Ltd., Key Facts
  • TauRx Therapeutics Ltd. - Pipeline by Indication, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Stage of Development, 2015
  • TauRx Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015
  • TauRx Therapeutics Ltd. - Phase III, 2015
  • TauRx Therapeutics Ltd. - Phase II, 2015
  • TauRx Therapeutics Ltd. - Phase I, 2015
  • TauRx Therapeutics Ltd. - Preclinical, 2015
  • TauRx Therapeutics Ltd. - Discovery, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Target, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Route of Administration, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Molecule Type, 2015
  • TauRx Therapeutics Ltd. - Pipeline Products by Mechanism of Action, 2015
  • TauRx Therapeutics Ltd. - Recent Pipeline Updates, 2015
  • TauRx Therapeutics Ltd. - Dormant Developmental Projects,2015
  • TauRx Therapeutics Ltd. - Discontinued Pipeline Products, 2015

List of Figures

  • TauRx Therapeutics Ltd. - Pipeline by Top 10 Indication, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Stage of Development, 2015
  • TauRx Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Top 10 Target, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • TauRx Therapeutics Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • TauRx Therapeutics Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top